Traditional cardiovascular risk assessment tools underperform among individuals with metabolic dysfunction-associated steatotic liver disease.

There is increased risk for atrial fibrillation in patients with implanted devices exposed to hot outdoor temperatures.

Early abdominal CT may be warranted among patients with unknown or uncertain biochemical screening results for primary aldosteronism.

MASLD rates have decreased, whereas liver fibrosis and cirrhosis rates have increased among US patients with type 2 diabetes since 2017.